U.S., Jan. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07319299) titled 'STOP HCC-GAAD-APAC-Thailand' on Nov. 15, 2025.
Brief Summary: Hepatocellular carcinoma (HCC) surveillance is frequently underutilized, and currently available biomarkers, such as alpha-fetoprotein (AFP), demonstrate suboptimal diagnostic performance. This prospective study aims to evaluate a simplified multivariate index, the GAAD score-comprising gender, age, alpha-fetoprotein (AFP), and protein induced by vitamin K absence or antagonist-II (PIVKA-II)-for its ability to improve the detection of hepatocellular carcinoma in patients with chronic liver disease.
The study hypothesizes that incorporation of the GAAD score into standard ...